Novo Just Paid $2.6 Billion for a Drug Nobody's Tested in Humans

That's an ambitious shopping list. And the Hengrui deal is Novo admitting it can't fill every shelf from its own labs.

Why Oral Matters More Than You Think

Most GLP-1 drugs today are injections. Patients stick a needle in their belly once a week. It works, but let's be honest: nobody loves needles.

An oral pill that achieves the same results would be a game-changer. It lowers the psychological barrier to starting treatment, simplifies the patient experience, and could dramatically expand the market. If you can pop a pill on Monday morning and not think about your obesity medication until next week, that's a very different proposition than a weekly injection.

HRS-1596 is designed to be exactly that: a once-weekly oral dual agonist. If the science works (big "if"), it could give Novo a differentiated weapon in a market increasingly crowded with injectables.

Novo isn't the only one chasing this format, though. Viking Therapeutics is developing an oral dual agonist. Roche's enicepatide posted positive Phase 2 data this year. And several Chinese biotechs, including Hengrui's own more advanced asset (ribupatide, already in Phase 3), are pushing hard. The oral obesity space is getting very, very competitive.

Is $2.6 Billion for a Preclinical Asset Actually Crazy?

It sounds wild. But context matters.

First, Novo isn't actually paying $2.6 billion today. It's paying $300 million now; the rest only comes due if the drug clears clinical trials, gets approved, and sells well. Those are massive "ifs" for a molecule this early. The real economic value is better understood as a probability-weighted bet, not a lump sum.

Second, this kind of deal isn't unprecedented. In 2022, Merck licensed seven preclinical antibody-drug conjugates from Kelun Biotech for up to $9.3 billion in total biobucks. AstraZeneca paid potentially over $5 billion for a preclinical RNA platform from an Imperial College spinout in 2021. Lilly struck a $2.75 billion preclinical deal with Insilico Medicine for AI-discovered therapeutics.

The pattern is clear: when a therapeutic area is white-hot, pharma pays up for early optionality. Obesity is the hottest area in the industry right now, and oral formulations are the frontier everyone wants to claim.

Third, the clinical risk is real but manageable for a company Novo's size. Most preclinical drugs fail. But $300 million is a rounding error on Novo's balance sheet, and the milestone structure means the company only pays more as risk gets removed. It's less like gambling at a casino and more like buying a call option: limited downside, massive upside if things work out.

The Bigger Picture

This deal is a signal flare. Novo's leadership has openly acknowledged that internal innovation alone won't be enough to fend off Lilly and the growing wave of challengers. The company is pursuing targeted acquisitions and partnerships to rebuild its late-stage pipeline, and this Hengrui license fits that playbook perfectly.

The competitive landscape tells the story. Lilly leads with tirzepatide. Roche and Viking are gaining ground with their own dual agonists. Chinese developers are flooding the market with fast-follow candidates. And lurking on the horizon are triple agonists like retatrutide that could leapfrog dual agonists entirely.

Novo's response? Buy more shots on goal. HRS-1596 is one of potentially five or more multi-blockbuster assets the company hopes to have by 2030.

What to Watch

The deal still needs U.S. antitrust clearance and is expected to close in Q4 2026. After that, the real test begins: can HRS-1596 produce the kind of weight-loss data in humans that justifies a $2.6 billion price tag?

Phase 1 results from the Chinese trials will be the first meaningful readout. If the drug shows strong efficacy and tolerability signals, Novo's bet will look prescient. If it stumbles (and plenty of promising preclinical drugs do), the $300 million upfront becomes an expensive lesson.

Either way, the message from Copenhagen is unmistakable: in the obesity drug wars, standing still isn't an option. Even if that means paying billions for a blueprint.

Merck Just Paid $400M for a Drug That Doesn't Exist Yet

Merck just dropped $400 million on a Chinese biotech's preclinical cancer drug targeting a protein scientists called "undruggable" for 40 years. The KRAS G12D race is on, and Merck's gamble says everything about where Big Pharma is shopping for its next blockbuster.